Novo Nordisk, Visionary Corporate Partner and Lead Benefactor of the Campaign for Our Future, has committed an additional $600,000 toward Phase II of the Campaign – Research is Our Future, which will focus on advancing NHF’s research program.
To officially launch the public phase of the Campaign, Dr. David Cooper, Director, Medical Affairs, and Mike Ferrara, Senior Brand Manager, Biopharmaceuticals, of Novo Nordisk presented NHF CEO Val Bias with a $600,000 check at the Leadership Weekend on Friday, February 26, 2010, at the Crystal Marriott Gateway Hotel in Arlington, VA. The check presentation was met with enthusiastic applause from representatives of 43 of NHF’s 46 chapters, who attended the event.
On the heels of the big announcement, chapter leaders participated in a session outlining available resources to help engage their membership in a national effort to raise funds toward better treatments and ultimately, cures, for bleeding disorders. The generous Novo Nordisk support served to kick start the Campaign, but has also helped to build the momentum for this effort to build individual support for Phase II. With only $450,000 left to raise to reach our $1.2 million goal, keeping this momentum going is critical as almost every major medical advancement in the treatment and care of people with bleeding disorders has been made possible through funding from caring individuals who understand firsthand the importance of scientific discovery.
NHF thanks our 2010 Corporate Partners of the Campaign for our Future: Visionary Corporate Partner and Lead Benefactor Novo Nordisk; Principal Corporate Partner Baxter; Major Corporate Partners Bayer HealthCare and CSL Behring; and Corporate Partner Grifols.
To learn more about Campaign for Our Future, Research is Our Future, please visit www.hemophilia.org/campaignforourfuture